Sightera Biosciences
Summary active Updated Jul 17, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Sightera Biosciences is an Antwerp-based AI drug discovery startup that spun out of the University of Antwerp (UA) and Antwerp University Hospital (UZA) in January 2026 12. Founded in January 2025 by Hendrik Vercammen (CEO), Maxim Le Compte (CSO), Lars Vanlommel (CBO), and Christophe Deben (CDO), the company trains its AI on proprietary data from patient-derived biological material — focusing on advanced, therapy-resistant, or end-stage disease biology (so-called “extreme biology”) — with initial applications in oncology and fibrosis 123.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-07-17 | Pre-Seed | €3M | Entourage, Anacura, QBIC | 123 |
The funding will support team expansion, platform build-out, advancement of Sightera’s lead molecular glue oncology programme toward preclinical candidate selection, and strategic partnerships with pharma and biotech 12.
What Investors Say
No independently sourced investor commentary found at time of announcement.
What Founders Say
No independently sourced founder testimonials found at time of announcement.
Sources
-
“Antwerp’s Sightera Biosciences raises €3 million to scale its patient-derived AI drug discovery platform,” EU-Startups, July 17, 2026. Accessed July 2026. https://www.eu-startups.com/2026/07/antwerps-sightera-biosciences-raises-e3-million-to-scale-its-patient-derived-ai-drug-discovery-platform/↩↩↩↩
-
“Sightera Biosciences closes €3M pre-seed to expand its patient-derived AI drug discovery platform,” Tech.eu, July 17, 2026. Accessed July 2026. https://tech.eu/2026/07/17/sightera-biosciences-closes-eur3m-pre-seed-to-expand-its-patient-derived-ai-drug-discovery-platform/↩↩↩↩
-
“Reversing AI drug discovery: Belgian biotech Sightera raises €3M to learn from ‘extreme’ patient biology first,” Tech Funding News, July 17, 2026. Accessed July 2026. https://techfundingnews.com/sightera-raises-3m-extreme-biology-ai-drug-discovery/↩↩